Physician profile
Ivan Sarria
NPI 1962650879
$2,140.30
in general payments reported to CMS, 2019-2025
21 companies · $678 in 2025
The $678 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $316 · 2023: $534 · 2024: $613 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,824.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $697.26 | 2022-2025 | Lo Loestrin Fe, Orilissa, Ubrelvy |
| Sage Therapeutics, LLC | $367.13 | 2024-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $149.45 | 2023-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $122.84 | 2023-2025 | |
| Phadia US INC. | $101.25 | 2023 | Immunocap |
| Optumhealth Care Solutions, LLC | $86.83 | 2024 | Vivify Health Care Team Portal 001, Eitan Medical |
| Agile Therapeutics, INC. | $78.51 | 2023-2024 | Twirla |
| Shield Therapeutics INC | $76.24 | 2025 | |
| Organon LLC | $75.95 | 2022-2024 | Nexplanon |
| Astellas Pharma US INC | $63.38 | 2024-2025 | Veozah |
| Supernus Pharmaceuticals, INC. | $61.52 | 2025 | Qelbree |
| Dexcom, INC. | $45.35 | 2024-2025 | Dexcom G6 Transmitter |
| Therapeuticsmd, INC. | $38.49 | 2022 | |
| Pfizer INC. | $32.65 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.38 | 2023-2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $23.40 | 2025 | Thinprep 2000 Processor |
| Myovant Sciences INC. | $21.55 | 2022 | |
| Merck Sharp & Dohme LLC | $21.13 | 2025 | Gardasil 9 |
| Verrica Pharmaceuticals INC. | $16.44 | 2024 | Ycanth |
| Exeltis, USA INC. | $15.61 | 2025 | Slynd |
| Evofem Biosciences, INC. | $14.94 | 2023 | Phexxi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Sarria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.